Generation Bio Co Stock Today
| GBIO Stock | USD 0.41 0.11 21.15% |
PerformanceModest
| Odds Of DistressHigh
|
Generation Bio is selling at 0.41 as of the 19th of July 2025; that is 21.15% down since the beginning of the trading day. The stock's open price was 0.52. Generation Bio has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 20th of April 2025 and ending today, the 19th of July 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 12th of June 2020 | Category Healthcare | Classification Health Care |
Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. Generation Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 67.04 M outstanding shares of which 767.01 K shares are currently shorted by private and institutional investors with about 3.76 trading days to cover. More on Generation Bio Co
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Generation Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsGeneration Bio can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Generation Bio's financial leverage. It provides some insight into what part of Generation Bio's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Generation Bio Co (GBIO) is traded on NASDAQ Exchange in USA. It is located in 301 Binney Street, Cambridge, MA, United States, 02142 and employs 115 people. Generation Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 34.95 M. Generation Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 67.04 M outstanding shares of which 767.01 K shares are currently shorted by private and institutional investors with about 3.76 trading days to cover.
Generation Bio Co currently holds about 301.17 M in cash with (88.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.07, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Generation Bio Probability Of Bankruptcy
Ownership AllocationGeneration Bio Co has a total of 67.04 Million outstanding shares. The majority of Generation Bio outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Generation Bio to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Generation Bio Co. Please pay attention to any change in the institutional holdings of Generation Bio as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Generation Ownership Details
Generation Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| State Street Corp | 2025-03-31 | 1 M | |
| Ubs Group Ag | 2025-03-31 | 977.3 K | |
| Morgan Stanley - Brokerage Accounts | 2025-03-31 | 878.9 K | |
| Squarepoint Ops Llc | 2025-03-31 | 439.3 K | |
| Los Angeles Capital Management Llc | 2025-03-31 | 378.9 K | |
| Northern Trust Corp | 2025-03-31 | 369.9 K | |
| Charles Schwab Investment Management Inc | 2025-03-31 | 356.4 K | |
| Td Asset Management Inc | 2025-03-31 | 340.7 K | |
| Jpmorgan Chase & Co | 2025-03-31 | 202 K | |
| T. Rowe Price Associates, Inc. | 2025-03-31 | 9.1 M | |
| Fmr Inc | 2025-03-31 | 4.8 M |
Generation Bio Historical Income Statement
Generation Stock Against Markets
Generation Bio Corporate Management
| Caitlin MBA | Senior Development | Profile | |
| Robert Kotin | CoFounder Advisor | Profile | |
| Sara Besten | Chief Officer | Profile | |
| Tracy Zimmermann | Chief Officer | Profile | |
| Phillip Samayoa | Chief Officer | Profile | |
| Jasmin Tower | Chief Officer | Profile | |
| MBA MD | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Generation Bio Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Generation Bio. If investors know Generation will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Generation Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.08) | Revenue Per Share | Quarterly Revenue Growth 1.149 | Return On Assets | Return On Equity |
The market value of Generation Bio is measured differently than its book value, which is the value of Generation that is recorded on the company's balance sheet. Investors also form their own opinion of Generation Bio's value that differs from its market value or its book value, called intrinsic value, which is Generation Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Generation Bio's market value can be influenced by many factors that don't directly affect Generation Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Generation Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Generation Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Generation Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.